Pfizer Inspra submission
Pfizer submits sNDA in April for use of its selective aldosterone blocker Inspra (eplerenone) for congestive heart failure. The sNDA is based on the EPHESUS trial, which showed a mortality reduction for post-MI patients receiving eplerenone (1Pharmaceutical Approvals Monthly March 1, p. 23). The firm said April 22 that Inspra would not be launched until the CHF indication is cleared; the antihypertensive was first approved Sept. 27, 2002, for hypertensio
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.